DoH Policies screened during the period: 1 April 2024 – 30 June 2024

In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.

Documents

NICE Technology Appraisal TA956 - Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (PDF 513KB)
PDF (512 KB)

NICE Technology Appraisal TA955 - Dupilumab for treating moderate to severe prurigo nodularis (PDF 514KB)
PDF (513 KB)

NICE Technology Appraisal TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (review of TA613 and TA301) (PDF 563KB)
PDF (562 KB)

NICE Technology Appraisal TA957 - Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (PDF 622KB)
PDF (622 KB)

NICE Technology Appraisal TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and overtreatments (PDF 513KB)
PDF (512 KB)

NICE Technology Appraisal TA959 - Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (PDF 510KB)
PDF (510 KB)

NICE Technology Appraisal TA962 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (PDF 515KB)
PDF (515 KB)

NICE Technology Appraisal TA963 - Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. (PDF 513KB)
PDF (512 KB)

NICE Technology Appraisal TA964 - Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (PDF 513KB)
PDF (512 KB)

NICE Clinical Guideline NG237 - Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management (partially updates and replaces CG191 (PDF 564KB)
PDF (563 KB)

NICE Technology Appraisal TA967 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (partial review of TA540) (PDF 514KB)
PDF (514 KB)

NICE Clinical Guideline NG239 - Vitamin B12 deficiency in over 16s: diagnosis and management (PDF 558KB)
PDF (558 KB)

The Firefighters’ Pension Schemes and Compensation Scheme (Amendment) Regulations (Northern Ireland) 2024 - Survivors’ Benefit and Correction of the Public Service Pensions Revaluation Orders (NI) for 2021 and 2022. (PDF 548KB)
PDF (547 KB)

NICE Technology Appraisal TA970 - Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (review of TA700) (PDF 511KB)
PDF (511 KB)

Draft Foster Placement & Fostering Agencies Regulations (Northern Ireland) (PDF 631KB)
PDF (630 KB)

NICE Technology Appraisal TA971 - Remdesivir and tixagevimab plus cilgavimab for treating COVID-19. (PDF 683KB)
PDF (682 KB)

NICE Technology Appraisal TA973 - Atogepant for preventing migraine (PDF 511KB)
PDF (511 KB)

NICE Clinical Guideline NG140 - Abortion care (PDF 517KB)
PDF (517 KB)

NICE Clinical Guideline NG241 - Ovarian cancer: identifying and managing familial and genetic risk (PDF 565KB)
PDF (564 KB)

NICE Technology Appraisal TA975 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (review of TA554) (PDF 514KB)
PDF (514 KB)

NICE Technology Appraisal TA974 - Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (review of TA700). (PDF 513KB)
PDF (513 KB)

NICE Technology Appraisal TA977 - Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (PDF 512KB)
PDF (512 KB)

‘Bereaved NI’ - Northern Ireland Bereavement Network website (PDF 533KB)
PDF (533 KB)

NICE Public Health Guideline NG212 - Mental wellbeing at work (PDF 514KB)
PDF (514 KB)

• Management of the prescribing of cow’s milk allergy formula in infants 12 months and over. (PDF 659KB)
PDF (658 KB)

Safe and Effective Staffing (PDF 522KB)
PDF (521 KB)

Help viewing documents